产品
编 号：F746480
分子式：C25H22ClF2N5O3
分子量：513.92
分子式：C25H22ClF2N5O3
分子量：513.92
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1640282-42-3
产品详情
生物活性：
Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases.
体内研究：
Zunsemetinib (1,000 ppm; p.o.) blocks LPS-induced TNF-α expression persisted for up to 4 weeks after dosing.Zunsemetinib (10 and 20 mg/kg; p.o.) increases bone density.Zunsemetinib prevents osteopenia in NOM IDc mice through inhibition of osteoclastogenesis.Animal Model:8-week-old WT female mice
Dosage:1,000 ppm
Administration:P.o.
Result:Blocked LPS-induced TNF-α expression persisted for up to 4 weeks after dosing.
Animal Model:Rats
Dosage:10 and 20 mg/kg
Administration:P.o.
Result:Increased bone density.
体外研究：
Zunsemetinib (1 and 10 μM; 1 hour; WT and NOM ID BMMs) has no effect on NLRP3 expression, but decreases IL-1β expression by promoting IL-1β mRNA degradation.Zunsemetinib (0.4 nM~1 μM; 16 hours; PBMC) reduces IL-1β secretion and promotes IL-1β mRNA instability.Zunsemetinib selectively blocks p38α MAPK activation of the proinflammatory kinase MK2 while sparing p38α activation of other effectors such as PRAK and ATF2. Zunsemetinib inhibits in vitro osteoclast formation induced by RANKL.
Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases.
体内研究：
Zunsemetinib (1,000 ppm; p.o.) blocks LPS-induced TNF-α expression persisted for up to 4 weeks after dosing.Zunsemetinib (10 and 20 mg/kg; p.o.) increases bone density.Zunsemetinib prevents osteopenia in NOM IDc mice through inhibition of osteoclastogenesis.Animal Model:8-week-old WT female mice
Dosage:1,000 ppm
Administration:P.o.
Result:Blocked LPS-induced TNF-α expression persisted for up to 4 weeks after dosing.
Animal Model:Rats
Dosage:10 and 20 mg/kg
Administration:P.o.
Result:Increased bone density.
体外研究：
Zunsemetinib (1 and 10 μM; 1 hour; WT and NOM ID BMMs) has no effect on NLRP3 expression, but decreases IL-1β expression by promoting IL-1β mRNA degradation.Zunsemetinib (0.4 nM~1 μM; 16 hours; PBMC) reduces IL-1β secretion and promotes IL-1β mRNA instability.Zunsemetinib selectively blocks p38α MAPK activation of the proinflammatory kinase MK2 while sparing p38α activation of other effectors such as PRAK and ATF2. Zunsemetinib inhibits in vitro osteoclast formation induced by RANKL.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备